A Study to Assess the Effect of Y-90 Therapy on Non-target/Background Liver

Study on Radioembolization Therapy for Liver Disease

Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

The primary question of interest is quantifying the relationship between Y-90 liver therapy and liver damage.

Detailed description of study

The purpose of this study is to look at the safety of radioembolization therapy with Yttrium 90 for liver disease.

Participants will not be paid for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: liver disease,HCC,liver cancer,hepatocellular carcinoma,hepatic cancer,liver,hepatic,carcinoma,cancer,hepatocellular
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:

  • Subjects must have a diagnosis of hepatocellular carcinoma (HCC) and a treatment plan to undergo radioembolization therapy with Y-90 at Indiana University Health Hospital.
  • Subjects must be willing and able to comply with all procedures and visits required for this protocol (pre-treatment, during treatment, and post-treatment).

For a full list of participation criteria, please visit clinicaltrials.gov.

Updated on 19 Feb 2024. Study ID: 1606072855 (RADY-BTG-TANN-HIDA/0603)

This study investigates the safety of radioembolization therapy using Yttrium 90 for treating liver disease. Radioembolization is a procedure that delivers radiation directly to the liver to target cancer cells, specifically for hepatocellular carcinoma (HCC).

Participants will undergo various procedures related to the therapy, including pre-treatment, during treatment, and post-treatment evaluations. These procedures are necessary to monitor the effects and safety of the treatment.

  • Who can participate: Adults diagnosed with hepatocellular carcinoma (HCC) who are planning to undergo Y-90 radioembolization therapy at Indiana University Health Hospital are eligible. Participants must be able to comply with all required procedures and visits.
  • Study details: Participants will receive radioembolization therapy with Yttrium 90, which involves delivering radiation directly to the liver.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here